|
注册号: Registration number: |
ChiCTR2400083439 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-25 09:30:31 |
|
注册时间: Date of Registration: |
2024-04-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
增加刺激时间、频率和强度的经颅直流电刺激对精神分裂症患者认知功能的影响:一项随机对照试验 |
|
Public title: |
Effects of transcranial direct current stimulation with increased stimulation time, frequency and intensity of treatment on cognitive function in patients with schizophrenia: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
增加刺激时间、频率和强度的经颅直流电刺激对精神分裂症患者认知功能疗效评价的研究 |
|
Scientific title: |
Study on the effect of transcranial direct current stimulation with increased stimulation time, frequency and intensity of treatment on cognitive function in patients with schizophrenia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡人钦 |
研究负责人: |
罗庆华 |
|
Applicant: |
Hu Renqin |
Study leader: |
Luo Qinghua |
|
申请注册联系人电话: Applicant telephone: |
+86 183 6853 6092 |
研究负责人电话:
Study leader's |
+86 189 8361 2632 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1754316886@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
202538@cqmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
|
Applicant address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
Study leader's address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
400016 |
研究负责人邮政编码: Study leader's postcode: |
400016 |
|
申请人所在单位: |
重庆医科大学附属第一医院精神科 |
||
|
Applicant's institution: |
Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院精神科 |
||
|
Affiliation of the Leader: |
Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-132-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-25 00:00:00 | ||
|
伦理委员会联系人: |
严青 |
||
|
Contact Name of the ethic committee: |
Yan Qing |
||
|
伦理委员会联系地址: |
中国重庆市渝中区袁家岗友谊路1号 |
||
|
Contact Address of the ethic committee: |
1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 8901 1876 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区袁家岗友谊路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究疾病: |
精神分裂症 |
||||||||||||||||||||||
|
Target disease: |
Schizophrenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要目的:探究阳极tDCS作用于左侧DLPFC时,对SZ患者认知功能的影响。 次要目的:1. 探究SZ患者结束tDCS疗程后,认知功能的变化情况。2.探究经阳极tDCS治疗后的SZ患者的阳性及阴性症状是否会减轻。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objective: To investigate the effects of anodal tDCS applied to the left DLPFC on the cognitive functions of patients with schizophrenia (SZ). Secondary objectives: 1. To explore the changes in cognitive functions of SZ patients after completing a course of anodal tDCS therapy. 2. To examine whether positive and negative symptoms in SZ patients are alleviated after treatment with anodal tDCS. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.存在严重的全身性疾病,包括但不限于严重的肝、肾、呼吸系统、心血管、内分泌疾病、血液病或肿瘤性疾病;2. DSM-V诊断为其他原发性精神疾病;3.电极部位的皮肤损伤或皮肤病; 4.使用金属植入物或任何电敏感支持设备的患者;5.可影响认知或对治疗反应的重大神经疾病(如中风、癫痫);6.怀孕或哺乳;7.接受重复经颅磁刺激(rTMS)或其他神经调节治疗;8.同时参与另一项临床试验 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Presence of severe systemic diseases, including but not limited to serious liver, kidney, respiratory, cardiovascular, endocrine diseases, hematologic disorders, or neoplastic diseases; 2. Diagnosed with other primary psychiatric disorders according to DSM-V; 3. Skin lesions or dermatological conditions at the electrode site; 4. Use of metal implants or any electro-sensitive support devices; 5. Significant neurological disorders that may affect cognition or treatment response (e.g., stroke, epilepsy); 6. Pregnancy or lactation; 7. Undergoing repetitive transcranial magnetic stimulation (rTMS) or other neuromodulatory treatments; 8. Participation in another clinical trial concurrently. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-30 00:00:00至 To 2025-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-05-01 00:00:00 至 To 2025-01-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
受试者将按照1:1随机分配至干预组或控制组。随机序列由不参与评估的研究助理使用 Microsoft Office Excel 2019产生,并使用不透光的密闭的信封保存。受试者签订知情同意书入组后,将由研究者按照受试者的入组顺序打开相应的信封,患者按照信封内的随机序列分配至控制组或者干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients included will be randomized by the ratio 1:1. Random sequences will be generated by a research associate using Microsoft Office Excel 2017 and kept by hospital nurses within envelopes which are sequentially numbered, sealed and opaque. Researchers will open the corresponding numbered envelope after consent. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
double blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和CABTAB软件自动保存的文档。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and the document automatically saved by CABTAB. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |